anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Non-gelatinous protein hydrolysate suitable for parenteral use is lyophilized in aqueous solution containing, in addition to the protein hydrolysate, a gelatin hydrolysate having a gel point of 15 to 20 DEG C. in 26 to 35% aqueous solution and being present in a ratio of 1 to 2 parts of gelatin hydrolysate to 9 parts of the non-gelatinous protein hydrolysate; it is stated that the foaming problem normally encountered does not become apparent to any appreciable extent when the partially hydrolysed gelatin is included. The gelatin hydrolysate may be made by hydrolysing an aqueous solution of gelatin for three hours at approximately 250 DEG F. and 15 lbs. per sq. inch pressure.  According to an example, to 1,470 ml. of 23% casein hydrolysate in which 69% of the total nitrogen was in the form of a -amino nitrogen, there was added 188 ml. of hydrolysed gelatin prepared as described above and containing 32% solids. Vitamins &c., dextrose and sodium ethyl mercurithiosalicylate were added and the total volume of the solution was brought up to 3,08 litres with warm pyrogenfree distilled water.  After filtering, 77 ml. portions of the solution filled into 250 ml. brown-glass bottles were frozen at -60 DEG F. and then placed in a lyophiliser, the pressure being decreased to 50-150 microms.  The bottles were finally removed from the lyophiliser and aseptically stoppered.  The product, which contained less than 5% of moisture, reconstituted readily with pyrogen-free distilled water.  Other examples are concerned with lyophilising bovine plasma and fibrin hydrolysates.
A device, system and components configured to be inserted or imbedded in an oral cavity of an animal or human for oral mucosa drug delivery system, OMDDS. The device includes a receptacle for one or more OMDDS with or without enhancer for drug delivery. The enhancer can assist in delivery via non-invasive or minimally invasive active or passive mythologies. The device is configured for several diseases including local and systemic disease. The device can replace invasive injections while reducing patient discomfort and pain. The device can be further configured to interface a plurality of one or more customizable functions and applications; including, but not limited to, auxiliary body biosensors, closed loop diagnosis and medication administration, data collections, alerting, reporting, communication network, preset biometrics and dose ranges. The system includes technology-integration, analytics, and wearables to accurately determine health referred to communication network of wearable drug delivery system.
FIELD: chemistry of cerebrosides. SUBSTANCE: method involves extraction of pig brain, extract separation, filtration, filtrate precipitation with 4-5 volumes of ethanol followed by purification of the end product by its washing with acetone at pH 3-4, dissolving in methanol and recrystallization from the mixture of equal volumes of chloroform and methanol. Extraction is carried out with 2-3 volumes of acetone at 30-40 C for 10-12 hr. Before precipitation with ethanol extract is cooled to 0-4 C and impurity precipitate is separated at 6-10 C for 2-4 hr. Filtrate is extracted with 2-4 volumes of ethyl ether at 20-25 C for 4-6 hr, solvent is distilled off under vacuum, residue is dissolved in pyridine at 50-60 C and solution is cooled at 0-2 C for 10-16 hr. Nervone is bioactive cerebroside and can be used in medicine at lipid metabolism disturbance and degenerative damage of the central nervous system. EFFECT: increased yield of nervone.
Sargramostim (GM-CSF) will start on Day +5 and continue until ANC \>1000 x3 days or \>1500 x1 day. GM-CSF will be administered not less than 24 hours after the last dose of cyclophosphamide and will be given at a dose of 250mcg/m2/day as an infusion over 2 hours.
Twenty-four young male and female athletes, specializing in athletics disciplines such as sprint (hurdles, 100m, 110m), and endurance: race walk, 5000m, and 10000m, volunteered to take part in this study. Investigation was held during 9 days of the training camp (preparatory period, general preparation sub-period), which was aimed at increasing the endurance and flexibility of athletes. During the training camp, all subjects occupied the same accommodations and followed the same training plan and diet schedules. The camp regime included 2 training sessions per day, lasting 4 hours per day, and a total of 21 hours per 9 days. Blood samples were taken always in the same conditions, from the antecubital veins. Participants were seated in a recumbent position for a minimum of 10 minutes before blood draws to stabilize the hydrostatic condition. Before collection of the first sample (rested baseline), participants were asked to avoid any intense exercise at least 24 hours before sampling. Next samples were taken after 4 days and after another 5 days of training camp (in total after 9 days). The concentration of catecholamines: epinephrine and norepinephrine in serum was measured as well and the responsiveness of the adrenal medulla to the sympathetic nervous activity was estimated by the ratio E/NE calculated. Also, concentrations of cortisol, hs-CRP, and myoglobin were measured and changes in blood morphology were estimated.
In order to calibrate the differential pressure measurement to a (approximately) zero difference in the ground height, the reference position determination section (2) is guided so close to the blood pressure measuring device (1) that a calibration signal is triggered if the minimum distance between two points respectively defined on the reference position determination section (2) and on the blood pressure measuring device (1) falls below a threshold value. A control device integrated into the blood pressure measuring device (1) or connected to the blood pressure measuring device (1) performs a calibration measurement as a reaction to the trigger signal. The triggering means are embodied as a reference position determination section RFID tag (10) and an associated blood pressure measuring device near field communication reading device (11). The near field communication reading device (11) in the blood pressure measuring device (1) triggers a calibration signal if it detects a correctly coded RFID tag in the reference position determination section (2). The reference position determining part (2) to be attached to the patient is preferably designed as a disposable item and has an associated increased sterility requirement. The reference position determination part is connected to the blood pressure measuring device by means of a tube connection (12) such that a continuous liquid column exists between a liquid reservoir (13) in the reference position determination part (2) and a correction pressure sensor (14) in the blood pressure measuring device (1).
A method has been developed for the formation of submicron particles (nanoparticles) by heat-denaturation of proteins (such as human serum albumin) in the presence of multivalent ions (such as calcium). Also provided are novel products produced by the invention method. An appropriate concentration of multivalent ions, within a relatively narrow range of concentrations, induces the precipitation of protein in the form of colloidal particles, at a temperature which is well below the heat denaturation temperature of the protein (as low as 60 ~C for serum albumin). Temperatures at which invention method operates are sufficiently low to permit incorporation of other molecules (e.g., by co-precipitation), into submicron particles according to the invention, including compounds which cannot withstand high temperatures. Invention methods facilitate the production of protein nanoparticles and microparticles containing various molecules (such as nucleic acids, oligonucleotides, polynucleotides, DNA, RNA, polysaccharides, ribozymes, pharmacologically active compounds, and the like) useful for therapeutic, diagnostic and other purposes. The addition of multivalent cations serves both to induce precipitation, and to allow linking of negatively charged molecules, such as DNA, to the negatively charged protein.
Cysteine hydrochloride injection, USP is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of neonates, including preterm infants, requiring total parenteral nutrition. The safety profile for cysteine hydrochloride injection, USP use in neonates includes risks of acid-base imbalance and hepatobiliary dysfunction.

Acid-base imbalance, including metabolic acidosis, and liver dysfunction may occur with cysteine hydrochloride injection, USP administration in preterm infants. Frequent clinical and laboratory assessments are necessary to monitor and manage fluid balance, electrolyte concentrations, liver tests, and acid-base balance during parenteral nutrition therapy [see Warnings and Precautions (5.4)].

Hyperammonemia is of special significance in neonates. This reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin. It is essential that blood ammonia be measured during treatment [see Warnings and Precautions (5.5)].

Because of immature renal function, neonates including preterm infants, receiving prolonged parenteral nutrition with cysteine hydrochloride injection, USP may be at higher risk of aluminum toxicity [see Warnings and Precautions (5.7)].
Systems and methods of monitoring medication compliance are provided. A first node receives from a second node a picture of a pill bottle label and a picture of the number of pills in the pill bottle. The information on the label is predicted from the picture of the pill bottle. The medication and number of pills is predicted from the picture of the number of pills. Information associated with compliance to the dosage regimen of the medication is determined based on the predicted number of pills and the dosage regimen. The second node sends to the first node an indication of the information associated with the medication compliance.
Deficient or inappropriate healing of bone impacts clinical decision-making and treatment options in orthopedics, oral and maxillofacial surgery, plastic surgery and periodontics. While a number of auto- and allografting techniques have been used to regenerate craniofacial defects caused by infective, neoplastic or trauma-induced bone loss, each method has significant limitations. Our research group in the Craniofacial and Skeletal Diseases Branch of NIDCR has developed methods to culture and expand cell populations derived from mouse bone marrow stroma. We believe that an important next step is to apply the information gained in animal studies to treat osseous defects in humans. We propose to examine the potential of cultured human bone marrow stromal cells to serve as an abundant source of osteoblastic progenitor cells. These cells will ultimately be used to graft craniofacial osseous defects. In the course of this study we will: (1) develop methods for the propagation and enrichment of osteoblastic progenitor cells from bone marrow stroma; (2) test various vehicles for the transfer of bone marrow stromal cells to osseous defects in recipient animals; (3) determine optimal culturing and transplantation conditions for the eventual transplantation of bone marrow stromal cells into human recipients. These studies will define the parameters of bone marrow stromal cell transplantation and will generate models for future therapeutic strategies.
The invention belongs to the field of medicine preparation, and specifically relates to a liposome preparation comprising a berbamine medicine, and a preparation method thereof. The liposome comprises the berbamine medicine, phospholipid, cholesterol, a hydrophilic lipid derivative, and a gradient establishment substance. A mass ratio of the medicine to phospholipid is 1:5-1:100, a mass ratio of cholesterol to phospholipid is 1:2-1:4, and a mass ratio of the hydrophilic lipid derivative to phospholipid is 1:2-1:6. The preparation method provided by the invention is feasible. With the method, the quality is controllable, such that the method is suitable for industrialized productions. The obtained berbamine medicine liposome has small particle size, uniform particle distribution, high encapsulation rate, and good stability. When the berbamine medicine is prepared into liposome, medicine blood circulation time can be effectively prolonged, tumor tissue targeting efficiency can be improved, and medicine in-vivo antitumor effect is enhanced. Or, a synergetic antitumor effect can be developed with the liposome and other chemotherapy medicines, toxicity can be reduced, and body immunity can be improved.
Peripheral benign lung tumors are often asymptomatic and incidentally detected on chest radiographs. Surgical intervention is recommended when feasible. Single-port thoracoscopic resection has emerged as a promising technique for treating various chest diseases, including lung tumors. This study aimed to assess the clinical efficacy of single-port thoracoscopic resection for benign lung tumors and its impact on respiratory function and inflammatory factors. A total of 128 eligible patients diagnosed with benign lung tumors were randomly assigned to either the observation group (undergoing single-port thoracoscopic resection) or the control group (undergoing conventional thoracic surgery). Surgical outcomes, complications, pulmonary and respiratory function, and inflammatory factors were compared between the two groups. The observation group showed significantly lower intraoperative bleeding, shorter hospitalization time, and lower complication rates compared to the control group. Patients in the observation group exhibited higher vital capacity (VC), forced vital capacity (FVC), and total lung capacity (TLC) levels at 1/2 week and 1 month after surgery. Additionally, forced expiratory volume in one second (FEV1) and maximum ventilation volume per minute (MVV) levels were higher in the observation group post-surgery, with a lower Borg score. Levels of C-reactive protein (CRP), precalcitonin (PCT), and tumor necrosis factor (TNF-α) were lower in the observation group post-surgery. Single-port thoracoscopic resection demonstrates favorable clinical efficacy for treating benign lung tumors, reducing bleeding, and shortening hospital stays. Furthermore, it improves lung and respiratory function while reducing inflammatory factors. This technique is safe, effective, and holds promise for wider application in managing benign lung tumors.
Cuffed TT sizes selected as follows: ID 3.0 mm for birth (\>3 kg body weight) to \< 8 months; ID 3.5 mm for 8 to \< 12 months (Salgo, Schmitz et al. 2006). Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to the depth marking in cuffed TTs.
Limited data are available on overdose of the components of ODEFSEY in patients. If overdose occurs, monitor the patient for evidence of toxicity. Treatment of overdose with ODEFSEY consists of general supportive measures including monitoring of vital signs and ECG (QT interval) as well as observation of the clinical status of the patient.

Emtricitabine (FTC): Hemodialysis treatment removes approximately 30% of the FTC dose over a 3-hour dialysis period starting within 1.5 hours of FTC dosing (blood flow rate of 400 mL per minute and a dialysate flow rate of 600 mL per minute). It is not known whether FTC can be removed by peritoneal dialysis.

Rilpivirine (RPV): Human experience of overdose with RPV is limited. There is no specific antidote for overdose with RPV. Since RPV is highly bound to plasma protein, dialysis is unlikely to result in significant removal of RPV.

Tenofovir Alafenamide (TAF): Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%.
The parameters for shock wave therapy will be: frequency 4-6 Hz, intensity 0.075-0.11 mJ/mm2 (millijoules per millimeter), number of pulses 350+10xcm2 (square centimetre) of wound surface (the number of pulsations is dependent of the surface), with sterile field (sterile gel on the wound and sterile transparent film to cover it). They will be applied by sweeping the surface of the wound and 1 centimetre around it. In each session, the session-specific data notebook and the appearance of side effects (pain, bleeding, others) will be recorded. Subsequently, the conventional healing procedure will be applied, according to the procedures for healing chronic wounds of the Guadarrama Hospital.
A method, a system, and a non-transitory storage medium are described in which a health monitoring, analyzing, and response service is provided. The service may ingest monitoring information from end devices. The service may assign an adaptive weight value to each instance of monitoring information based on profile information pertaining to the end device. The profile information may include operational characteristics information and rating information. The service may aggregate the monitoring information based on the adaptive weight values to produce a weighted health or state value. The service may analyze and determine a health or condition of a person or object. The service may also generate response information reactive to the determined health or condition.
The INT arm will receive the 7-step web-based ImPaC intervention to use over 6 months. The intervention is divided into the Plan Stage and the Change Stage. The Plan Stage (steps 1-4) is expected to be completed in 1 month. The Change Stage (steps 5-7) is expected to be completed in 1-2 months. We anticipate that Change Teams will be able to complete 2 cycles of change over the 6-month intervention period.
The invention relates to a method for producing, amongst other things, amino-acid and/or hydroxycarboxylic-acid metal chelates, a solvent-free mixture of at least one metal oxide, metal hydroxide, metal carbonate or oxalate, and the solid organic acid is subjected to intensive mechanical stress. According to the invention, this is done in that the reaction partners are introduced in particle form into a fluid stream of a fluid-bed countercurrent mill operating without grinding elements, wherein mechanical activation of at least one of the reaction partners is effected by collision processes within a reaction chamber formed in a region of the fluid stream, and a solid body reaction to form the metal chelate is triggered. The novel method operates very energy-efficiently and with a high specific yield. It leads to a product having compact particles in the small, single-digit micrometer range having a comparatively narrow particle size distribution and a large surface. The product is homogenous and very pure. Thermal loading or decomposition of the organic chelate ligands, in particular of the amino acids, is likewise avoided, as are contaminants from milling and grinding element abrasion.
An increasing body of evidence suggests that acylphosphatase-2 (ACYP2) polymorphisms are correlated with an increased susceptibility to a range of malignancies. Nevertheless, its potential functions, molecular mechanisms in hepatocellular carcinoma (HCC) and whether it can be act as a therapeutic target remain uninvestigated. Herein, ACYP2 was found to be lowly expressed in HCC and was negatively correlated with tumor size, tumor differentiation, microvascular invasion and the prognosis of HCC patients. Functional investigations revealed that overexpression of ACYP2 inhibited the proliferation and metastasis of HCC cells while promoting apoptosis; knockdown of ACYP2 had the exact opposite effect. Additionally, it was observed that ACYP2 was distributed in both the cytoplasm and nucleus of HCC cells. According to the mechanistic studies, the expression of potassium calcium-activated channel subfamily N member 4 (KCNN4) was negatively regulated by cytoplasmic ACYP2, resulting in the inhibition of K+ outflow and subsequent inactivation of the ERK pathway, which impeded the growth and metastasis of HCC. Furthermore, the activity of telomerase reverse transcriptase (TERT) was inhibited by nuclear ACYP2, leading to the reduction in length of telomeres and consequent reversal of HCC cell immortalization. Additionally, a novel targeted nanotherapy strategy was developed wherein the pcDNA-ACYP2 vector was encapsulated within polyetherimide nanoparticles (PEI/NPs), which were subsequently coated with HCC cell membranes (namely pcDNA/PEI/NPs@M). Safety and targeting characteristics abound for these nanocomposites, in both subcutaneous graft tumor models and orthotopic mouse models, they inhibited the progression of HCC by impeding TERT activity and the KCNN4/ERK pathway. In conclusion, our research identifies novel molecular mechanisms involving cytoplasmic and nuclear ACYP2 that inhibit the progression of HCC. Moreover, pcDNA/PEI/NPs@M represents a targeted therapeutic strategy for HCC that holds great promising.
Volunteers with prehypertension, but otherwise healthy, will complete a screening visit, then be admitted to the In-Patient Unit for fourteen (14) days. Participants will be admitted for 5 days during the week and then go on pass for 2 weekend days each week with packed DASH diet meals. During hospitalization we will: 1) collect samples of blood and urine daily 2) monitor blood pressure, weight and pulse twice daily 3) collect 24-hour urine, twice during the period of two weeks 4) serve participants a menu based on DASH principles, namely low in sodium and high in potassium.
Remineralization gel containing calcium glycerophosphate (R.O.C.S.® Medical Minerals Gel, Russia) will be put into the Essix appliance with a reservoir for 5-7 minutes twice a day for one month. Before and after the applying remineralization gel, the laser fluorescence values will measure with a DIAGNOdent pen( KaVo Dental corporation, East Main street Lake Zurich, lL).
The present invention discloses a drug carrier with thermal sensitivity, a manufacturing method thereof, and use of the same as a NMR contrast agent. The drug carrier comprises nano-magnetic particles, drugs and a composite polymer. The nano-magnetic particles and drugs are encapsulated in the composite polymer. The composite polymer is made of self-assembly polymers formed of a water-soluble polymer (such as poly vinyl alcohol) and a thermosensitive copolymer (such as Pluronic F68 or Pluronic F127) by a self-assembly method. When an external magnetic field is applied, the nano-magnetic particles generate heat so as to increase a predetermined temperature range (about 37-50 DEG C), thereby resulting in the volume change of the drug carrier. Therefore, the drug carrier is changed, destructed and collapsed to lead a rapid drug release.
The present invention relates to a kind of drug payroll management methods, comprising: a. issues dispensing according to prescription information and instructs；B. by the drug dispensing in prescription into medicine basket, medicine basket is distributed to foreground window；C. judge whether there is refrigeration medicine in the medicine basket of foreground window, if there is refrigerating medicine, then judge whether the refrigeration medicine is overtime, enters step d, otherwise goes to step e；D. if the refrigeration medicine time-out, the medicine basket equipped with the refrigeration medicine light a kind of lamp of color, otherwise go to step e；E. judge whether prescription medicine is provided overtime: if prescription medicine provides time-out, the medicine basket equipped with the prescription medicine lights the lamp of another color, and otherwise go to step f；F. patient's medicine basket when taking medicine equipped with patient drug of swiping the card lights the lamp of the third color.The invention further relates to a kind of drug release management systems.The present invention can improve the overstocked problem of the medicine basket occurred in drug distribution process, and provide advantageous support in terms of dispensing time-out, refrigeration medicine take out.